What science can do体育外围app官网

Annual Report and Form 20-F
Information 2018
外围投注app有哪些

01

外围投注app有哪些

This Annual Report quick-阅读 provides top-level 资讯rmation on our business and the progress we have made in 2018 in pushing the boundaries of science to deliver life-changing medicines and demonstrating what science can do.



Science can


Science can


Science can


Science can


Science can


02

外围投注app有哪些


In 2018, under the leadership of Pascal Soriot, and together with the entire talented AstraZeneca 团队, we delivered on our promise and returned a reinvigorated AstraZeneca to 产品介绍 Sales growth. We succeeded because we have been true to our Value of following the science. We also succeeded because we put patients first.

Leif Johansson, Chairman

I am pleased to report that, in 2018, after the previous six years in which revenues had fallen by 更多 than one third, we turned the corner and returned to 产品介绍 Sales growth, driven by a new generation of medicines from our therapy areas.

Pascal Soriot, Chief Executive Officer

03

外围投注app有哪些

2018 marked our return to 产品介绍 Sales growth with strong performance from Growth Platforms and New Medicines 更多 than offsetting the continued impact from patent expiries.


体育外围app官网


Total Revenue*
体育外围app官网

$22.1bn体育外围app官网


Net cash flow from operating activities
Down 27% at actual rate of exchange to $2,618 million




体育外围app官网

$2.6bn体育外围app官网

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

*Total Revenue consists of Product Sales and Externalisation Revenue.

 

体育外围app官网


Reported operating profit
Down 8% at actual rate of exchange to $3,387 million (down 7% at CER)
体育外围app官网

$3.4bn体育外围app官网


Core operating profit
Down 17% at actual rate of exchange to $5,672 million (down 17% at CER)
体育外围app官网

$5.7bn体育外围app官网

体育外围app官网


Reported EPS
Down 28% at actual rate of exchange to $1.70 (down 29% at CER)
体育外围app官网

$1.70体育外围app官网


Core EPS
Down 19% at actual rate of exchange to $3.46 (down 19% at CER)
体育外围app官网

$3.46体育外围app官网



04

外围投注app有哪些

We are a global science-led business delivering medicines to patients through innovative science and excellence in development and commercialisation.


外围投注app有哪些


Total Product Sales
外围投注app有哪些

$21,049m外围投注app有哪些

2017: $20,152m
2016: $21,319m
体育外围app官网


外围投注app有哪些



外围投注app有哪些




外围投注app有哪些


体育外围app官网

体育外围app官网

体育外围app官网

体育外围app官网

体育外围app官网

体育外围app官网


外围投注app有哪些



外围投注app有哪些

Broadening access to healthcare

 



外围投注app有哪些

Furthering ethics and transparency

 



外围投注app有哪些

Protecting the environment

 




外围投注app有哪些



外围投注app有哪些

$0.90体育外围app官网

Pence: 68.4
SEK: 7.92
Payment date: 10 September 2018
体育外围app官网


外围投注app有哪些

$1.90体育外围app官网

Pence:146.8
SEK: 17.46
Payment date: 27 March 2019
体育外围app官网


外围投注app有哪些

$2.80体育外围app官网

Pence: 215.2
SEK: 25.38

体育外围app官网


05

外围投注app有哪些

We announced our strategy for returning to growth in 2013. The first phase in our journey was focused on rebuilding our pipeline. The second stage was crucial as we drove our Growth Platforms forward, continued to launch new medicines and made them available to patients. We returned to Product Sales growth in 2018 and, as we look ahead to 2020 and beyond, continued investment in our product launches and pipeline will keep us on track to deliver sustainable growth in line with our targets.

We are a ‘pure-play’, global, science-led pharmaceutical company. We are focused on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of unmet medical need in three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism (CVRM); and Respiratory. In 2018, our strategic priorities were focused under the three pillars listed below.



2018 Highlights


2018 Highlights


2018 Highlights


外围投注app有哪些